

July 18, 2023

**Zeon Announces Investment in Knowledge Palette, Inc.**

Zeon Corporation

**Zeon Corporation (Zeon; head office: Chiyoda-ku, Tokyo; President and CEO: Tetsuya Toyoshima) has invested in Knowledge Palette, Inc. (Knowledge Palette; head office: Kawasaki-shi, Kanagawa; Representative Directors: Masakazu Fukuda and Hiroki Danno), a company developing AI drug discovery technology based on single-cell transcriptome analysis\*1.**

Knowledge Palette applies the world's most accurate single-cell transcriptome analysis technology (Quartz-Seq2) to obtain large-scale data on the state of cells that cause diseases. The company intends to develop new drugs and treatments efficiently by using this data and AI technology to elucidate the causes of diseases and contribute to overcoming those deemed incurable. Zeon will support the company by sharing the technologies and other resources of the Zeon Group as a chemical manufacturer in Japan and overseas, to accelerate the development of technologies to build platforms of drug discovery and regenerative medicines, which could be applied to a wider range of diseases.

Zeon is committed to contributing to a sustainable society and providing indispensable products and services by investing in and nurturing startups in four key areas (healthcare and life sciences, CASE and MaaS\*2, telecommunications (5G/6G), and energy conservation) and ultimately realizing a sustainable Earth and safe and comfortable life for people.



**Outline of Knowledge Palette**

Company Name: Knowledge Palette, Inc.  
Business: Developing technologies for drug discovery and regenerative medicines  
Representative Directors: Masakazu Fukuda, Hiroki Danno  
Address: 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan  
URL: <https://www.knowledge-palette.com/en/>

\*1 Single-cell transcriptome analysis (Quartz-Seq2)

One of Knowledge Palette's core technologies, single cell transcriptome analysis, was developed by Dr. Danno, Dr. Nikaido, Dr. Sasagawa, and their colleagues at RIKEN (Sasagawa, et al. 2018, Genome Biology) for the purpose of obtaining comprehensive gene expression profiles at the single-cell level to identify cell type and state with high accuracy. This technology was ranked as number one for both accuracy and overall scores by an international benchmark project in 2020.

\*2 CASE: Connected, Autonomous, Shared & Services, and Electric; MaaS: Mobility as a Service

For more information, contact:

Department of Corporate Communication, Corporate Sustainability Division, Zeon Corporation

Phone: +81-3-3216-2747